PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29844863-3	2018	We have designed and tested both in vitro and in vivo, a monoamine oxidase B (MAOB) specific prodrug, PAM-OBG, that is converted by glioma MAOB into the MGMT inhibitor O6-benzylguanine (O6BG) and the DNA crosslinking agent acrolein.	O(6)-benzylguanine	168-184	monoamine oxidase B	Homo sapiens	57-76	
29844863-3	2018	We have designed and tested both in vitro and in vivo, a monoamine oxidase B (MAOB) specific prodrug, PAM-OBG, that is converted by glioma MAOB into the MGMT inhibitor O6-benzylguanine (O6BG) and the DNA crosslinking agent acrolein.	O(6)-benzylguanine	168-184	monoamine oxidase B	Homo sapiens	78-82	
29844863-3	2018	We have designed and tested both in vitro and in vivo, a monoamine oxidase B (MAOB) specific prodrug, PAM-OBG, that is converted by glioma MAOB into the MGMT inhibitor O6-benzylguanine (O6BG) and the DNA crosslinking agent acrolein.	O(6)-benzylguanine	168-184	monoamine oxidase B	Homo sapiens	139-143	
29844863-3	2018	We have designed and tested both in vitro and in vivo, a monoamine oxidase B (MAOB) specific prodrug, PAM-OBG, that is converted by glioma MAOB into the MGMT inhibitor O6-benzylguanine (O6BG) and the DNA crosslinking agent acrolein.	O(6)-benzylguanine	186-190	monoamine oxidase B	Homo sapiens	57-76	
29844863-3	2018	We have designed and tested both in vitro and in vivo, a monoamine oxidase B (MAOB) specific prodrug, PAM-OBG, that is converted by glioma MAOB into the MGMT inhibitor O6-benzylguanine (O6BG) and the DNA crosslinking agent acrolein.	O(6)-benzylguanine	186-190	monoamine oxidase B	Homo sapiens	78-82	
29844863-3	2018	We have designed and tested both in vitro and in vivo, a monoamine oxidase B (MAOB) specific prodrug, PAM-OBG, that is converted by glioma MAOB into the MGMT inhibitor O6-benzylguanine (O6BG) and the DNA crosslinking agent acrolein.	O(6)-benzylguanine	186-190	monoamine oxidase B	Homo sapiens	139-143